ARDELYX, INC. Available-for-sale Securities, Gross Realized Gain (Loss)
ARDELYX, INC. (ARDX) reported Available-for-sale Securities, Gross Realized Gain (Loss) of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-17.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet · last filed 2017-02-17
- ARDELYX, INC. available-for-sale securities, gross realized gain (loss) for the quarter ending 2016-12-31 was $0.00.
- ARDELYX, INC. available-for-sale securities, gross realized gain (loss) for the quarter ending 2016-09-30 was $0.00.
- ARDELYX, INC. available-for-sale securities, gross realized gain (loss) for fiscal 2016 was $0.00.
| Period end | Available-for-sale Securities, Gross Realized Gain (Loss) 3 month | Available-for-sale Securities, Gross Realized Gain (Loss) 6 month | Available-for-sale Securities, Gross Realized Gain (Loss) 9 month | Available-for-sale Securities, Gross Realized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $0.00 derived: sum of 2 quarters · filed 2017-02-17 | $0.00 10-K · filed 2017-02-17 | |
| 2016-09-30 | $0.00 10-Q · filed 2016-11-07 | $0.00 10-Q · filed 2016-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |